Altruist Biologics Launches Altru-CON™ High-Concentration Formulation Platform to Accelerate Biologics Development
Published on 03/18/2026 at 02:09 | prnewswire.co.uk
Altru-CON™ harnesses proprietary excipient blends and expertise to maximize drug delivery and stability through high-concentration formulation.The platform can reduce IND timelines to under nine months and achieve stable formulation for up to 200 mg/mL subcutaneous administration.View original content:https://www.prnewswire.co.uk/news-releases/altruist-biologics-launches-altru-con-high-concentration-formulation-platform-to-accelerate-biologics-development-302702704.html
en | boerse | 68767369 |
